Drug Profile


Alternative Names: AGS-003; AGS-003-LNG

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Argos Therapeutics Inc
  • Developer Argos Therapeutics Inc; GU Research Network; National Cancer Institute (USA); Roswell Park Cancer Institute
  • Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Renal cell carcinoma
  • Phase II Non-small cell lung cancer

Most Recent Events

  • 05 Feb 2018 Argos Therapeutics enters into an option agreement to license anti-PD1 monoclonal antibodies from Pharmstandard and Actigen
  • 12 Sep 2017 Additional efficacy and immunogenicity data from the phase III trial in Renal cell carcinoma presented at the Annual Congress of European Society for Medical Oncology (ESMO-2017)
  • 18 Apr 2017 Efficacy data from a post-hoc analysis and immunogenicity data from a pre-defined immunological analysis of the phase III ADAPT trial in Renal cell carcinoma released by Argos Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top